STANLEY M. LEMON, M.D., (Vice-chair), is Dean of the School of Medicine at the University of Texas Medical Branch at Galveston. He received his undergraduate degree in biochemical sciences from Princeton University summa cum laude and his M.D. with honors from the University of Rochester. He completed postgraduate training in internal medicine and infectious diseases at the University of North Carolina at Chapel Hill, and is board-certified in both areas. From 1977 to 1983, he served with the U.S. Army Medical Research and Development Command, directing the Hepatitis Laboratory at the Walter Reed Army Institute of Research. He joined the faculty of the University of North Carolina School of Medicine in 1983, serving first as Chief of the Division of Infectious Diseases, and then Vice Chair for Research of the Department of Medicine. In 1997, Dr. Lemon moved to the University of Texas Medical Branch as Professor and Chair of the Department of Microbiology & Immunology. He was subsequently appointed Dean pro tem of the School of Medicine in 1999, and permanent Dean of Medicine in 2000. Dr. Lemon’s research interests relate to the molecular virology and pathogenesis of the positive-stranded RNA viruses responsible for hepatitis C and hepatitis A. He is particularly interested in the molecular mechanisms controlling replication of these RNA genomes and related mechanisms of disease pathogenesis. In addition, he has a longstanding interest in vaccine development. Dr. Lemon has published more than 180 papers and numerous textbook chapters related to hepatitis and other viral infections. He chaired the Anti-Infective Drugs Advisory Committee and the Vaccines and Related Biologics Advisory Committee of the U.S. Food and Drug Administration, as well as the Steering Committee on Hepatitis and Poliomyelitis of WHO’s Programme on Vaccine Development. From 2000 to 2002, he chaired the Institute of Medicine (IOM) Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance. At present, he is chairman of the U.S. Hepatitis Panel of the U.S.–Japan Cooperative Medical Science Program and cochair of the IOM/ NRC Committee on Advances in Technology and the Prevention of their Application to Next Generation Biowarfare Agents.
DAVID ACHESON, M.D., is Chief Medical Officer at the Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration. He received his medical degree at the University of London. After completing internships in general surgery and medicine, he continued his postdoctoral training in Manchester, England, as a Wellcome Trust Research Fellow. He subsequently was a Wellcome Trust Training Fellow in Infectious Diseases at the New England Medical Center and at the Wellcome Research Unit in Vellore, India. Dr. Acheson was Associate Professor of Medicine, Division of Geographic Medicine and Infectious Diseases, New England Medical Center until 2001. He then joined the faculties of the Department of Epidemiology and Preventive Medicine and Department of Microbiology and Immunology at the University of Maryland Medical School. Currently at the FDA, his research concentration is on foodborne patho-